Seeking Alpha

The FDA finds that a heart stent developed by Stryker (SYK) might not be worth the additional...

The FDA finds that a heart stent developed by Stryker (SYK) might not be worth the additional risks for patients because it offers no added benefits over existing drugs used to help prevent strokes. (report)
From other sites
Comments (1)
  • Koshien Kid
    , contributor
    Comments (196) | Send Message
     
    The FDA's job is to determine whether or not a device or a compound is safe for patients. Its job is most emphatically NOT to assess the cost-benefit relationship for a particular treatment; that is up to the patient and his or her physician, subject to whatever constraints are imposed by the patient's ability to fund the treatment.
    This smells like a very sneaky effort on the part of the current administration to squeeze rationing into their PPACA scheme.
    21 Mar 2012, 09:13 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs